Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

  • Revenue in JPY (TTM)3.59tn
  • Net income in JPY197.39bn
  • Incorporated1925
  • Employees47.35k
  • Location
    Takeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
  • Phone+81 332782111
  • Fax+81 332782000
  • Websitehttps://www.takeda.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
4502:TYO since
Adaptate Biotherapeutics LtdAnnounced10 Jan 202210 Jan 2022Announced18.84%--
Data delayed at least 20 minutes, as of Aug 12 2022 07:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Merck KGaA2.87tn453.36bn3.26tn62.77k24.683.154.791.167.617.6148.1859.700.45621.975.02347,266.907.
Astellas Pharma Inc1.35tn118.21bn3.79tn14.52k32.642.4717.502.8063.9663.96733.49844.440.57141.743.3793,087,
HALEON PLC1.60tn242.93bn4.55tn22.80k17.210.9663--2.620.16240.16241.072.89------432,719.30--------62.76--15.68--2.85457.600.2888---3.51--21.40------
Takeda Pharmaceutical Co Ltd3.59tn197.39bn6.19tn47.35k31.050.96077.781.72126.39126.392,296.994,085.660.26881.364.5275,862,610.001.481.861.732.2467.7568.855.506.980.74853.530.4215123.9411.6115.56-38.8114.8910.680.00
Chugai Pharmaceutical Co Ltd1.21tn389.01bn6.27tn7.66k15.794.70--5.20236.46236.46732.88794.740.83111.964.71157,319,400.0026.8216.0732.4019.4166.0861.1732.2623.473.08--0.0044.3827.0415.2541.1041.4114.8834.40
Bayer AG6.62tn580.60bn7.02tn101.91k12.031.346.061.054.314.3149.2238.700.3981.713.47485,331.803.51-1.374.71-1.7761.8959.998.82-3.730.83765.450.5388--6.484.76106.42-23.200.2547-5.52
Data as of Aug 12 2022. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

19.33%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 29 Jul 202268.06m4.30%
BlackRock Fund Advisorsas of 01 Jul 202151.07m3.23%
The Vanguard Group, Inc.as of 05 Aug 202239.18m2.48%
Daiwa Asset Management Co. Ltd.as of 29 Jul 202231.19m1.97%
Nikko Asset Management Co., Ltd.as of 05 Aug 202230.74m1.94%
Norges Bank Investment Managementas of 31 Dec 202123.31m1.47%
BlackRock Japan Co., Ltd.as of 30 Jun 202123.22m1.47%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 04 Aug 202215.14m0.96%
Geode Capital Management LLCas of 10 Aug 202212.24m0.77%
Canada Pension Plan Investment Boardas of 31 Mar 202211.62m0.73%
More ▼
Data from 31 Dec 2021 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.